Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Financial Results for the Fiscal Year Ended September 30, 2025 [Japanese GAAP] (Non-consolidated)
Kringle Pharma, The Current Fiscal Year's Net Income to Widen
[Delayed]Kringle Pharma Launches U.S. Subsidiary to Drive Global Growth
Analyst Report Released by Shared Research Inc.
Financial Results for the Nine Months Ended June 30, 2025 [Japanese GAAP](Non-consolidated)
Kringle Pharma, Oct-Jun (Cumulative 3Q) Net Income Loss Widens, Apr-Jun Net Income Loss Widens
Kringle Pharma, Net Income Forecast for the Fiscal Year Loss to Narrow
Analyst Report Released by Shared Research Inc.
U.S. FDA Orphan Drug Designation Granted to Recombinant Human HGF, KP-100IT,for the Treatment of Acute Spinal Cord Injury
[Delayed]Financial Results for the Six Months Ended March 31, 2025[Japanese GAAP](Non-consolidated)
Kringle Pharma, First Half Ordinary Profit Loss Widens, Jan-Mar Ordinary Profit Loss Widens
Analyst Report Released by Shared Research Inc.
[Delayed]Financial Results for the Three Months Ended December 31, 2024[Japanese GAAP](Non-consolidated)
Kringle Pharma, Oct-Dec (1Q) Ordinary Profit Loss Widens
Analyst Report Released by Shared Research Inc.
[Delayed]Financial Results for the Fiscal Year Ended September 30, 2024[Japanese GAAP](Non-consolidated)
Kringle Pharma,Inc., The Current Fiscal Year's Net Income to Widen